The limited availability of drug classes to treat fungal diseases underscores the necessity, for new antifungal medications. Presently three options exist,. Their efficacy is compromised by various drawbacks such as host toxicity, drug resistance and unwanted side effects. Consequently these issues hinder their effectiveness in practice. The prevalence of infections has notably increased in recent decades accompanied by alarmingly high fatality rates. Moreover the emergence of resistance patterns including resistance to multiple antifungal classes poses a significant concern. Extensive research on the mechanisms of resistance and pathogenicity has revealed potential targets for future antifungal therapies. In the quest for chemicals researchers are employing diverse strategies like screening of the product based on chemical genomics and repurposing existing medications. However need newlly antifungal medicines the current drug research in pipeline. Some potential compounds are in the stages of clinical development each, with a distinct mechanism of action. Thus it is crucial to continue forging with the development of antifungal medications to address the shortcomings of existing treatments, combat resistance and reduce mortality rates associated with invasive fungal infections. The exploration of targets and the implementation of screening techniques bring a promising outlook, for the future. However significant progress is required to fulfill the growing need, for medications that're truly efficient.